When to consider a diagnosis of MODY at the presentation of diabetes: aetiology matters for correct management

Br J Gen Pract. 2016 Jun;66(647):e457-9. doi: 10.3399/bjgp16X685537.

Authors

Agata Juszczak¹, Rebecca Pryse², Andrew Schuman³, Katharine R Owen⁴

Affiliations

¹ Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford.
² The Swan Practice, Buckingham.
³ 19 Beaumont St Surgery, Oxford.
⁴ Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford; Oxford National Institute for Health Research (NIHR) Biomedical Centre, Churchill Hospital, Oxford.

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Age of Onset
Diabetes Mellitus, Type 2 / diagnosis*
Diabetes Mellitus, Type 2 / genetics
Diabetes Mellitus, Type 2 / therapy
Diagnosis, Differential
Female
General Practice*
Genetic Testing
Gliclazide / therapeutic use*
Glucokinase / genetics*
Hepatocyte Nuclear Factor 1-alpha / genetics*
Humans
Hypoglycemic Agents / therapeutic use*
Male
Mutation
Practice Guidelines as Topic
Risk Reduction Behavior
Syndrome

Substances

HNF1A protein, human
Hepatocyte Nuclear Factor 1-alpha
Hypoglycemic Agents
Glucokinase
Gliclazide